Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Cencora

Are Wall Street Analysts Bullish on Cencora Stock?

Cencora has consistently outperformed the broader market over the past year, and analysts are maintaining a strongly bullish outlook on the company’s growth and earnings potential.

Barchart

What You Need to Know Ahead of Cencora's Earnings Release

Cencora is scheduled to report its second-quarter results next month, and analysts project a single-digit increase in earnings.

Barchart

Is Cencora Stock Outperforming the S&P 500?

Due to Cencora's outperformance relative to the broader S&P 500 Index, Wall Street analysts remain strongly optimistic about the stock’s outlook.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

What to Expect From Cencora's Next Quarterly Earnings Report

Cencora is set to report its first-quarter earnings next month, and analysts are anticipating a single-digit increase in its bottom line.

Barchart

How Is Cencora’s Stock Performance Compared to Other Medical Stocks?

While Cencora’s recent performance has lagged behind other healthcare stocks, analysts express strong confidence in its long-term growth potential.

Barchart

3 Stocks at Fresh 52-Week AND Record Highs to Buy Now

Both the NYSE and Nasdaq had more stocks hitting new 52-week highs than lows yesterday. Among the many choices were three stocks also hitting all-time highs. All three have the potential to maintain momentum in the near and long term.

Barchart

Cencora Stock: Is Wall Street Bullish or Bearish?

Pharma distributor Cencora has continued to outpace the broader market over the past year, and analysts remain strongly bullish on the stock’s prospects.

Barchart

Read news from The Economist, FT, and more,
with one subscription

What to Expect From Cencora's Q4 2025 Earnings Report

Cencora is scheduled to release its fourth-quarter results next month, with analysts projecting double-digit earnings growth.

Barchart

Cencora Stock: Is COR Outperforming the Health Care Sector?

Cencora has outperformed the Health Care sector over the past year, and analysts are highly optimistic about the stock’s prospects.

Barchart

Cencora Stock: Analyst Estimates & Ratings

Cencora has outpaced the broader market over the past year, and Wall Street analysts maintain a highly optimistic outlook on the stock’s prospects.

Barchart

Cencora Says Famed GLP-1 Class Products Drive Growth, Boosts Profit Outlook

Cencora, Inc. (NYSE:COR) on Wednesday reported third-quarter 2025 sales increased 8.7% to $80.66 billion, beating the consensus of $80.354 billion.

Benzinga

Here's What to Expect From Cencora's Next Earnings Report

Cencora is scheduled to release its second-quarter results next month, with analysts projecting double-digit earnings growth.

Barchart

Is Cencora Stock Outperforming the Dow?

Due to Cencora’s strong performance relative to the broader Dow over the past year, Wall Street analysts remain bullish about the stock’s prospects.

Barchart

Do Wall Street Analysts Like Cencora Stock?

Cencora has significantly outperformed the broader market over the past year, and analysts remain strongly bullish on the stock’s prospects.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Earnings Preview: What To Expect From Cencora's Report

Cencora is scheduled to report its second-quarter results next month, with analysts projecting a single-digit earnings growth.

MarketBeat

Top 3 S&P 500 Winners in a Losing Market

Despite a broad market correction in 2025, three S&P 500 stocks have defied the downturn, delivering standout performance and showcasing strong fundamentals.

Barchart

This ‘Recession-Proof’ Stock Just Set New Highs and Is Flashing ‘Buy’ Signals

Drug stocks like Cencora tend to be recession-proof, making today’s Chart of the Day especially relevant following a tariffs-driven selloff.

Barchart

Is Cencora Stock Outperforming the Nasdaq?

As Cencora has outperformed relative to the broader Nasdaq Composite over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Cencora Stock Outlook: Is Wall Street Bullish or Bearish?

Despite Cencora's underperformance relative to the broader market over the past year, Wall Street analysts remain bullish on the stock's future.

Barchart

Cencora's Quarterly Earnings Preview: What You Need to Know

As Cencora prepares to release its first-quarter earnings this month, analysts project a modest single-digit bottom-line surge.

Barchart

Is Cencora Stock Underperforming the S&P 500?

Cencora has trailed the S&P 500 index over the past year, but analysts remain highly bullish about the stock’s prospects.

Barchart

Are Wall Street Analysts Predicting Cencora Stock Will Climb or Sink?

Cencora has underperformed the broader market over the past year, and Wall Street analysts appear moderately bullish about the stock’s future.

Barchart

Cencora's Q4 2024 Earnings: What to Expect

Cencora is poised to announce its fourth-quarter results next month, and analysts predict a double-digit growth in the company’s bottom-line figure.

Barchart

How Is Cencora's Stock Performance Compared to Other Healthcare Stocks?

Cencora has outperformed other healthcare stocks over the past year and analysts remain bullish about the stock’s prospects.

Barchart

Is Wall Street Bullish or Bearish on Cencora Stock?

Cencora has outperformed the broader market over the past year, and Wall Street analysts remain bullish about the stock's prospects.

1 2

People

Howard Marks

26 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Places

United States

386,442 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.